FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

Analysts at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Monday, June 3rd.

FibroGen Price Performance

NASDAQ FGEN opened at $0.42 on Thursday. FibroGen has a one year low of $0.33 and a one year high of $2.93. The firm has a market cap of $41.78 million, a P/E ratio of -0.17 and a beta of 0.69. The stock’s 50-day moving average is $0.61 and its 200-day moving average is $1.12.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same quarter last year, the business posted ($0.65) earnings per share. Equities analysts anticipate that FibroGen will post -0.91 EPS for the current year.

Institutional Investors Weigh In On FibroGen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 DIFC Ltd grew its stake in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 45,990 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 280,161 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in FibroGen in the second quarter valued at $130,000. Doheny Asset Management CA acquired a new stake in FibroGen in the 2nd quarter valued at $48,000. Finally, AQR Capital Management LLC lifted its position in FibroGen by 139.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 769,586 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.